WA
CRSP icon

Waverly Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Waverly Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$862K Buy
18,124
+3,617
+25% +$191K 0.01% 878
2025
Q4 		$761K Buy
14,507
+114
+0.8% +$6.83K 0.01% 849
2025
Q3 		$933K Sell
14,393
-997
-6% -$57.2K 0.01% 660
2025
Q2 		$749K Buy
15,390
+143
+0.9% +$5.53K 0.01% 688
2025
Q1 		$519K Sell
15,247
-248
-2% -$10.5K 0.01% 760
2024
Q4 		$610K Sell
15,495
-3,897
-20% -$184K 0.01% 639
2024
Q3 		$911K Buy
19,392
+1,907
+11% +$96.8K 0.02% 459
2024
Q2 		$944K Buy
17,485
+8,404
+93% +$486K 0.02% 439
2024
Q1 		$619K Buy
9,081
+4,774
+111% +$342K 0.01% 441
2023
Q4 		$270K Buy
+4,307
New +$238K 0.01% 375
2023
Q3 		– Sell
-4,557
Closed -$256K – 408
2023
Q2 		$256K Buy
+4,557
New +$259K 0.01% 318

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Waverly Advisors's CRSP Position: Q1 2026 in Review

Waverly Advisors increased its CRISPR Therapeutics (CRSP) stake by 25% in Q1 2026, buying an estimated $191K and bringing the position to 18,124 shares worth $862K. The position accounts for 0.01% of the portfolio, ranked #878.

Waverly Advisors first reported a position in CRSP in Q2 2023 and has held it in 11 quarters since. The position peaked at $944K in Q2 2024. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Waverly Advisors held 18,124 shares of CRISPR Therapeutics worth $862K as of Q1 2026.
  • Waverly Advisors bought 3,617 CRISPR Therapeutics shares in Q1 2026, an estimated $191K.
  • CRISPR Therapeutics made up 0.01% of Waverly Advisors's portfolio in Q1 2026, its #878 holding.
  • Waverly Advisors first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • Waverly Advisors's CRISPR Therapeutics position peaked at $944K in Q2 2024.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Waverly Advisors's 13F filing for Q1 2026, filed 15 May 2026.